<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04019015</url>
  </required_header>
  <id_info>
    <org_study_id>OHSU IRB 17077</org_study_id>
    <nct_id>NCT04019015</nct_id>
  </id_info>
  <brief_title>Prehospital Kcentra for Hemorrhagic Shock</brief_title>
  <official_title>A Prospective Randomized Prehospital Trial Comparing Kcentra Plus Standard of Care to Standard of Care Alone in Trauma Patient With Hemorrhagic Shock</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot trial being performed to evaluate the feasibility, to include the ability of&#xD;
      EMS to identify patients in shock and the ability to package, store, and administer Kcentra&#xD;
      in the field.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Prospective randomized trials have shown that 4-factor prothrombin complex concentrate&#xD;
      (4FPCCs) result in more rapid correction of coagulopathy and greater likelihood of achieving&#xD;
      hemostasis in patients receiving vitamin K antagonists who require emergent operations or who&#xD;
      are bleeding. 4FPCCs have not been studied in the pre-hospital setting as a primary&#xD;
      resuscitative adjunct. The investigators believe the effects of Kcentra to prevent or treat&#xD;
      coagulopathy early after injury combined with its ability to treat the endotheliopathy of&#xD;
      trauma and prevent organ failure will results in improved outcomes in severely injured trauma&#xD;
      patients with hemorrhagic shock. The investigators have chosen to study a population of&#xD;
      trauma patients in severe hemorrhagic shock (SBP &lt; 70mmHg) because this population is at&#xD;
      greatest risk for developing acute coagulopathy of trauma and has the greatest potential to&#xD;
      benefit from the proposed therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 15, 2021</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of study drug administration</measure>
    <time_frame>First 24 hours after injury</time_frame>
    <description>Number of study drug kits opened and given to patients prior to hospital arrival.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>First 30 days after injury</time_frame>
    <description>To evaluate mortality at 3 hour, 24 hour, and 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Free Days</measure>
    <time_frame>First 30 days after injury</time_frame>
    <description>Number of days out of the hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU Free Days</measure>
    <time_frame>First 30 days after injury</time_frame>
    <description>Number of days out of the ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilator Free Days</measure>
    <time_frame>First 30 days after injury</time_frame>
    <description>Number of days not on a ventilator</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood Transfusions</measure>
    <time_frame>First 24 hours after injury</time_frame>
    <description>The amount of blood products transfused in the first 24 hours</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">166</enrollment>
  <condition>Trauma Injury</condition>
  <arm_group>
    <arm_group_label>Kcentra</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of Kcentra based on estimated body weight&#xD;
2000 U for patients with an estimated body weight ≤ 75kg&#xD;
3000 U for patients with an estimated body weight &gt; 75kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>A single infusion of volume matched placebo solution (Normal Saline)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prothrombin Complex Concentrate, Human</intervention_name>
    <description>Prothrombin Complex Concentrate (PCC) prepared from human plasma and contains blood coagulation factors</description>
    <arm_group_label>Kcentra</arm_group_label>
    <other_name>Kcentra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Normal saline solution</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Trauma patients age 18 years or greater, or weight &gt; 50 kg if age unknown&#xD;
&#xD;
          2. Systolic blood pressure &lt; 70 mmHg&#xD;
&#xD;
          3. Suspicion of hemorrhagic shock based on mechanism of injury&#xD;
&#xD;
          4. EMS transport to a participating trauma center&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Age less than 18&#xD;
&#xD;
          2. Unknown time of injury&#xD;
&#xD;
          3. Out-of-hospital cardiopulmonary resuscitation&#xD;
&#xD;
          4. Known history of thromboembolic disorders or stroke or suspicion by EMS of a recent&#xD;
             stroke&#xD;
&#xD;
          5. Known oral anti-coagulant use to include warfarin and novel anti-coagulants&#xD;
&#xD;
          6. Severe hypothermia (&lt;28°C)&#xD;
&#xD;
          7. Drowning or asphyxia due to hanging&#xD;
&#xD;
          8. Burns more than 20% total body surface area&#xD;
&#xD;
          9. Evidence of devastating blunt traumatic brain injury to include fixed and dilated&#xD;
             pupils, asymmetric pupils and extrusion of brain matter&#xD;
&#xD;
         10. Isolated blunt or penetrating head injury&#xD;
&#xD;
         11. Isolated spinal cord injury&#xD;
&#xD;
         12. Ground level (same level) falls&#xD;
&#xD;
         13. Inability to obtain intravenous access&#xD;
&#xD;
         14. Inability to administer randomized therapy within 4 hours of ambulance notification&#xD;
&#xD;
         15. Known transfers and inter-facility transfers&#xD;
&#xD;
         16. Known Do Not Resuscitate (DNR) prior to randomization&#xD;
&#xD;
         17. Known or suspected pregnancy&#xD;
&#xD;
         18. Known prisoners&#xD;
&#xD;
         19. Patients who have activated the &quot;opt-out&quot; process&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin A Schreiber, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 2, 2019</study_first_submitted>
  <study_first_submitted_qc>July 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2019</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Martin A Schreiber, MD</investigator_full_name>
    <investigator_title>Professor and Chief of Trauma</investigator_title>
  </responsible_party>
  <keyword>Shock, Hemorrhagic</keyword>
  <keyword>Trauma</keyword>
  <keyword>Mortality</keyword>
  <keyword>Wounds and Injuries</keyword>
  <keyword>Hemorrhage</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Hemorrhagic</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

